{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:24:27Z","timestamp":1781864667261,"version":"3.54.5"},"reference-count":23,"publisher":"The Pediatric Pharmacy Association","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Management of anemia of chronic kidney disease (CKD) often includes subcutaneous or intravenous administration of erythropoietin-stimulating agents (ESAs). Mircera, a pegylated continuous erythropoietin receptor agonist, has a longer duration of action and requires less frequent administration than other ESAs. Pediatric experience with Mircera is limited. We retrospectively reviewed our long-term experience of Mircera in a national pediatric nephrology center.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>Patients were identified via an electronic patient record database. Data collected included demographics (sex, age, etiology of CKD, CKD stage, dialysis modality), dosing information, and laboratory data\u2014hemoglobin (Hb), parathormone (PTH), ferritin, hematinics prior to commencing Mircera and all subsequent values associated with dose adjustments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Seventy-seven patients aged 2 to 18 years, with CKD stages 2 to 5T had received at least 1 dose of Mircera, with 75 patients having sufficient data and a total of 1473 doses. No patients discontinued Mircera owing to adverse effects. One patient experienced a potential severe adverse drug reaction. Mircera was effective in improving or maintaining Hb \u226510.0 g\/dL in most (58\/75, 77.3%) patients. The median dose to achieve Hb \u226510.0 g\/dL was 2.1 \u00b5g\/kg\/4 wk. Most doses (1039, 71.5%) were administered 4-weekly. The doses (161, 11.1%) that were administered 6-weekly remained efficacious. Thirty-two patients started Mircera with Hb &amp;lt;10.0 g\/dL; 26 (81%) achieved Hb \u226510.0 g\/dL within a median time of 4 months. Mircera was less effective if given every 8 weeks, or in the presence of hyperparathyroidism or hyperferritinemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSION<\/jats:title>\n                  <jats:p>Mircera appears safe and effective in pediatric patients with CKD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.5863\/1551-6776-28.6.509","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T17:48:22Z","timestamp":1698688102000},"page":"509-518","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Experience of a Long-acting Pegylated Erythropoietin-Stimulating Agent in Pediatric Chronic Kidney Disease"],"prefix":"10.5863","volume":"28","author":[{"given":"Maria Anna","family":"Bantounou","sequence":"first","affiliation":[{"name":"School of Medicine and Dentistry (MAB), University of Aberdeen, Aberdeen, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lamb","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology (AL, IJR, BCR), Royal Hospital for Children, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Mathematics and Statistics (DY), University of Strathclyde, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian James","family":"Ramage","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology (AL, IJR, BCR), Royal Hospital for Children, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben Christopher","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology (AL, IJR, BCR), Royal Hospital for Children, Glasgow, United Kingdom"},{"name":"University of Glasgow (BCR), Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","published-online":{"date-parts":[[2023,10,28]]},"reference":[{"key":"2023111414185291500_i2331-348X-28-6-509-b1","article-title":"Chronic Kidney Disease: Assessment and Management","author":"National Institute for Health and Care Excellence","year":"2021"},{"issue":"(2)","key":"2023111414185291500_i2331-348X-28-6-509-b2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00467-017-3663-y","article-title":"Anemia in chronic kidney disease","volume":"33","author":"Atkinson","year":"2018","journal-title":"Pediatr Nephrol"},{"issue":"(4)","key":"2023111414185291500_i2331-348X-28-6-509-b3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1053\/j.ackd.2005.07.008","article-title":"Anemia in children with chronic kidney disease","volume":"12","author":"Greenbaum","year":"2005","journal-title":"Adv Chronic Kidney Dis"},{"issue":"(11)","key":"2023111414185291500_i2331-348X-28-6-509-b4","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrneph.2011.115","article-title":"Anemia in children with chronic kidney disease","volume":"7","author":"Atkinson","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"(1)","key":"2023111414185291500_i2331-348X-28-6-509-b5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s12882-017-0688-1","article-title":"Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease","volume":"18","author":"Mikhail","year":"2017","journal-title":"BMC Nephrol"},{"key":"2023111414185291500_i2331-348X-28-6-509-b6","unstructured":"Martindale. Epoetins.\n          2022. Accessed May 13, 2022. https:\/\/www-medicinescomplete-com.knowledge.idm.oclc.org\/#\/content\/martindale\/16635-r?hspl=epoetins."},{"key":"2023111414185291500_i2331-348X-28-6-509-b7","author":"Martindale. Darbepoetin alfa","year":"2022"},{"key":"2023111414185291500_i2331-348X-28-6-509-b8","unstructured":"European Medicines Agency. European public assessment report\u202f: MIRCERA (scientific discussion). 2007. Accessed May 3, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion\/mircera-epar-scientific-discussion_en.pdf"},{"key":"2023111414185291500_i2331-348X-28-6-509-b9","unstructured":"Biochempeg. PEGylation of therapeutic proteins: development and challenge. 2020. Accessed May 13, 2022. https:\/\/www.biochempeg.com\/article\/90.html"},{"issue":"(6)","key":"2023111414185291500_i2331-348X-28-6-509-b10","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2215\/CJN.00730306","article-title":"Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease","volume":"1","author":"Macdougall","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023111414185291500_i2331-348X-28-6-509-b11","unstructured":"Roche. Mircera solution for injection in pre-filled syringe. 2021. Accessed May 13, 2022. https:\/\/www.medicines.org.uk\/emc\/medicine\/19960"},{"issue":"(3)","key":"2023111414185291500_i2331-348X-28-6-509-b12","doi-asserted-by":"crossref","first-page":"e001888","DOI":"10.1136\/bmjopen-2012-001888","article-title":"Anaemia management with C.E.R.A. in routine clinical practice: OCEANE (CohorteMircera patients non-dialys\u00e9s), a national, multicenter, longitudinal, observational prospective study, in patients with chronic kidney disease not on dialysis","volume":"3","author":"Frimat","year":"2013","journal-title":"BMJ Open"},{"key":"2023111414185291500_i2331-348X-28-6-509-b13","first-page":"CD009904","article-title":"Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease","volume":"8","author":"Saglimbene","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"(3)","key":"2023111414185291500_i2331-348X-28-6-509-b14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1399-3046.2011.01476.x","article-title":"Effective treatment of anemia in pediatric kidney transplant recipients with methoxy polyethylene glycol-epoetin beta","volume":"15","author":"Wedekin","year":"2011","journal-title":"Pediatr Transplant"},{"issue":"(8)","key":"2023111414185291500_i2331-348X-28-6-509-b15","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00467-011-1846-5","article-title":"Continuous EPO receptor activator therapy of anemia in children under peritoneal dialysis","volume":"26","author":"Cano","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"(1)","key":"2023111414185291500_i2331-348X-28-6-509-b16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2215\/CJN.03570417","article-title":"Efficacy and long-term safety of C.E.R.A. maintenance in pediatric hemodialysis patients with anemia of CKD","volume":"13","author":"Fischbach","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"(11)","key":"2023111414185291500_i2331-348X-28-6-509-b17","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2215\/CJN.01640309","article-title":"Measurement and estimation of GFR in children and adolescents","volume":"4","author":"Schwartz","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"(Suppl3)","key":"2023111414185291500_i2331-348X-28-6-509-b18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(03)00905-3","article-title":"Bone metabolism and disease in chronic kidney disease","volume":"42","author":"Eknoyan","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"(6)","key":"2023111414185291500_i2331-348X-28-6-509-b19","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3945\/ajcn.114.103366","article-title":"Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review","volume":"102","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Clin Nutr"},{"issue":"(Suppl3)","key":"2023111414185291500_i2331-348X-28-6-509-b20","first-page":"i803","article-title":"FC037: A study to ascertain the optimum starting dose of subcutaneous (SC) C.E.R.A. for maintenance treatment of anemia in pediatric patients with chronic kidney disease (CKD) on dialysis or not yet on dialysis","volume":"37","author":"Warady","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2023111414185291500_i2331-348X-28-6-509-b21","unstructured":"Kidney Disease Improving Global Outcomes. Kidney Disease Improving Global Outcomes Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney International Supplements. 2012. Accessed July 8, 2022. https:\/\/kdigo.org\/wp-content\/uploads\/2016\/10\/KDIGO-2012-Anemia-Guideline-English.pdf"},{"issue":"(8)","key":"2023111414185291500_i2331-348X-28-6-509-b22","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/ndt\/gfaa048","article-title":"The problem with transferrin saturation as an indicator of iron \u2018sufficiency\u2019 in chronic kidney disease","volume":"36","author":"Besarab","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"(1)","key":"2023111414185291500_i2331-348X-28-6-509-b23","doi-asserted-by":"crossref","first-page":"8343","DOI":"10.1038\/s41598-021-87401-w","article-title":"Low serum iron is associated with anemia in CKD stage 1\u20134 patients with normal transferrin saturations","volume":"11","author":"Yu","year":"2021","journal-title":"Sci Rep"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/28\/6\/509\/3288934\/i2331-348x-28-6-509.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/28\/6\/509\/3288934\/i2331-348x-28-6-509.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:37:51Z","timestamp":1738780671000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/28\/6\/article-p509.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,10,28]]},"published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-28.6.509","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,1]]}}}